DL-Penicillamine NEW
| Price | $32 | $68 | $109 |
| Package | 10mg | 25mg | 50mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-16 |
Product Details
| Product Name: DL-Penicillamine | CAS No.: 52-66-4 |
| Purity: ≥98% | Supply Ability: 10g |
| Release date: 2024/11/16 |
Product Introduction
Bioactivity
| 名稱 | DL-Penicillamine |
| 描述 | DL-Penicillamine (3-Sulfanylvaline) is a chelating agent recommended for the removal of excess copper in patients with Wilson's disease. DL-Penicillamine is only found in individuals that have used or taken this drug. It is the most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease. From in vitro studies which indicate that one atom of copper combines with two molecules of DL-penicillamine. DL-Penicillamine also reduces excess cystine excretion in cystinuria. This is done, at least in part, by disulfide interchange between DL-penicillamine and cystine, resulting in the formation of penicillamine-cysteine disulfide, a substance that is much more soluble than cysteine and is excreted readily. DL-Penicillamine interferes with the formation of cross-links between tropocollagen molecules and cleaves them when newly formed. The mechanism of action of DL-penicillamine in rheumatoid arthritis is unknown although it appears to suppress disease activity. Unlike cytotoxic immunosuppressants, DL-penicillamine markedly lowers IgM rheumatoid factor but produces no significant depression in absolute levels of serum immunoglobulins. Also unlike cytotoxic immunosuppressants which act on both, DL-penicillamine in vitro depresses T-cell activity but not B-cell activity. |
| 存儲(chǔ)條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | DMSO : Insoluble H2O : 5 mM |
| 關(guān)鍵字 | DL-Penicillamine | DL Penicillamine | DLPenicillamine |
| 相關(guān)產(chǎn)品 | Neomycin sulfate | Sulfamethoxazole sodium | Doxycycline |
| 相關(guān)庫(kù) | FDA上市及藥典收錄分子庫(kù) | 經(jīng)典已知活性庫(kù) | 上市藥物庫(kù) | 藥物功能重定位化合物庫(kù) | NO PAINS 化合物庫(kù) | FDA 上市藥物庫(kù) | 已知活性化合物庫(kù) |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $32.00/10mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-16 | |
| $0.00/25KG |
PNP Biotech Co. Ltd
|
2022-09-29 | ||
| $1.00/1KG |
VIP6Y
|
Career Henan Chemical Co
|
2020-02-04 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY